Does BEXAROTENE Cause Malignant neoplasm progression? 26 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 26 reports of Malignant neoplasm progression have been filed in association with BEXAROTENE (Bexarotene). This represents 3.4% of all adverse event reports for BEXAROTENE.
26
Reports of Malignant neoplasm progression with BEXAROTENE
3.4%
of all BEXAROTENE reports
17
Deaths
5
Hospitalizations
How Dangerous Is Malignant neoplasm progression From BEXAROTENE?
Of the 26 reports, 17 (65.4%) resulted in death, 5 (19.2%) required hospitalization, and 3 (11.5%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BEXAROTENE. However, 26 reports have been filed with the FAERS database.
What Other Side Effects Does BEXAROTENE Cause?
Drug ineffective (67)
Hypothyroidism (65)
Death (53)
Hypertriglyceridaemia (44)
Off label use (32)
Disease progression (28)
Blood cholesterol increased (27)
Pruritus (24)
Nausea (22)
Blood triglycerides increased (20)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which BEXAROTENE Alternatives Have Lower Malignant neoplasm progression Risk?
BEXAROTENE vs BEZAFIBRATE
BEXAROTENE vs BEZLOTOXUMAB
BEXAROTENE vs BGB-11417
BEXAROTENE vs BICALUTAMIDE
BEXAROTENE vs BICTEGRAVIR